Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 11, 1999, Pages 2690-2696

  Yasukawa, Tsutomu ^a   Kimura, Hideya ^a   Tabata, Yasuhiko ^b   Miyamoto, Hideki ^a   Honda, Yoshihito ^a   Ikada, Yoshito ^b   Ogura, Yuichiro ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; POLYVINYL ALCOHOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CATTLE; CELL DIVISION; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; CYCLOHEXANES; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAVENOUS; MICROSCOPY, FLUORESCENCE; MICROSPHERES; PIGMENT EPITHELIUM OF EYE; POLYVINYL ALCOHOL; RABBITS; RHODAMINES; SESQUITERPENES; SOLUBILITY;

EID: 0032848664     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol. 1993; 111:1200-1209.
2. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189-1199.
3. Macular Photocoagulation Study (MPS) Group. Evaluation of argon green vs krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the macular photocoagulation study. Arch Ophthalmol. 1994;112:1176-1184.
4. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500-509.
5. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994;112:489-499.
6. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112: 480-488.
7. Macular Photocoagulation Study Group. The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. Arch Ophthalmol. 1995;113:190-194.
8. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101:1384-1396.
9. Ormerod LD, Puklin JE, Frank RN. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology. 1994;101: 1201-1210.
10. Sasai K, Murata R, Mandai M, et al. Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report. Int J Radiat Oncol Biol Phys. 1997;39:173-178.
11. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy. Br J Ophthalmol. 1993;77:265-273.
12. Bergink GJ, Hoyng CB, Van Der Maazen RWM, Deutman AF, Van Daal WAJ. Visual acuity and scar size in eyes with age-related subfoveal choroidal neovascular lesions, 30 months after radiation therapy. Doc Ophthalmol. 1996;92:61-75.
13. Tsujikawa M, Sawa M, Lewis JM, et al. Choroidal damage caused by the excision of choroidal neovascularization. Am J Ophthalmol. 1998;126:348-357.
14. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer. 1994;69:212-216.
15. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer. 1996;14: 2520-2527.
16. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972;175:409-416.
17. Noguchi A, Takahashi T, Yamaguchi T, et al. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconjug Chem. 1992;3:132-137.
18. Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol. 1995;47:479-486.
19. Takakura Y, Kitajima M, Matsumoto S, Hashida M, Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge, I: physicochemical characteristics and in vivo antitumor activity. Int J Pharmacol. 1987;37:135-143.
20. Takakura Y, Atsumi R, Hashida M, Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge, II: disposition and pharmacokinetics following intravenous and intramuscular administration. Int J Pharmacol. 1987;37:145-154.
21. Takakura Y, Takagi A, Hashida M, Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharmacol Res. 1987;4:293-300.
22. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharmacol Sci. 1994;83:601-606.
23. Murakami Y, Tabata Y, Ikada Y. Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection. Drug Delivery. 1997;4:23-31.
24. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991;142:257-265.
25. Kimura H, Sakamoto T, Hinton DR, et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci. 1995;36:2110-2119.
26. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348:555-557.
27. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun. 1991;174:1070-1076.
28. Maier JA, Delia D, Thorpe PE, Gasparini G. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs. 1997;8:238-244.
29. Antoine N, Bours V, Heinen E, Simar LJ, Castronovo V. Simulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst. 1995;87:136-139.
30. Hudson AE, Ko L, Brasel C, Bischoff J. The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem Biophys Res Commun. 1996;225:141-145.
31. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153.
32. Hori K, Li HC, Saito S, Sato Y. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br J Cancer. 1997;75:1730-1734.
33. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58:439-451.
34. Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 1996;13:57-64.
35. Haraguchi M, Okamura M, Konishi M, et al. Anti-angiogenic compound (TNP-470) inhibits mesangial cell proliferation in vitro and in vivo. Kidney Int. 1997;51:1838-1846.
36. Jain RH. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039-3051.
37. Casley-Smith JR, Clodius L, Foldi-Borcsok E, Gruntzig J, Foldi M. The effects of chronic cervical lymphostasis on regions drained by lymphatics and by prelymphatics. J Pathol. 1978;124:13-17.